Stockscreener 앱 받기
2.29%
시간 외 거래:
Pfizer Inc 주식(PFE)의 최신 뉴스
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts - Yahoo Finance
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments - GuruFocus.com
Investors Purchase High Volume of Call Options on Pfizer (NYSE:PFE) - MarketBeat
Pfizer cost cutting leads to Tampa layoffs - The Business Journals
Pfizer gets FDA accelerated approval for Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment - Marketscreener.com
Pfizer to lay off 62 in Tampa - Business Observer
Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer - Business Wire
Pfizer (NYSE:PFE) Trading Up 1.6%What's Next? - MarketBeat
Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Phenobarbital Market CAGR of 5% Trends and Growth Analysis By 2024 to 2031 | Sanofi, Pfizer Inc., Novartis AG, - EIN News
Principal Financial Group Inc. Sells 1,349,308 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts - BioSpace
Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ. - Law360
Why Pfizer (PFE) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Colleagues Celebrate Native American Heritage - Pfizer
Pfizer (NYSE:PFE) Trading 0.4% HigherTime to Buy? - MarketBeat
Liposomal Doxorubicin Market to Witness Massive Growth | Major Giants Pfizer, Ipsen, Johnson & Johnson - openPR
Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance? - Investor's Business Daily
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26? - Yahoo Finance
PFIZER INC : Gets a Neutral rating from UBS - Marketscreener.com
Stomach Cancer Drugs Market Future Business Opportunities - openPR
Pfizer's SWOT analysis: stock outlook amid pipeline progress and cost cuts - Investing.com
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Jim Cramer’s Take on Pfizer (PFE): Can CEO Dr. Bourla’s Bold Strategy Overcome Debt and Turn the Stock Around? - Yahoo Finance
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis) (NYSE:PFE) - Seeking Alpha
Satellite Images Reveal Russian Military Movements in Syria - Yahoo Finance
Pfizer (NYSE:PFE) Shares Down 0.4% Following Analyst Downgrade - MarketBeat
Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call (PFE) - Seeking Alpha
Pfizer eyes 2025 revenue growth despite post-COVID challenges, activist pressure - MM+M Online
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations - Yahoo Finance
Pfizer reiterated at Market Perform by analyst following FY25 guidance - Investing.com Canada
Truist cuts Pfizer shares target, retains buy rating on growth projections - Investing.com
Pfizer: Jefferies confirms its analysis on the stock - Marketscreener.com
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy - Yahoo! Voices
Trending tickers: The latest investor updates on Pfizer, Micron, Nissan, Teva and National Grid - Yahoo Finance UK
Pfizer provides full-year 2025 guidance - The Pharma Letter
Pfizer aims to quell concern about its vaccine business under Trump - Crain's New York Business
Pfizer Sets 2025 Outlook, Confirms 2024 Guidance - Mirage News
Oncology Drugs Market Huge Growth in Future Scope 2024-2031 | - openPR
Epilepsy Drugs Market Detailed In New Research Report 2024 | - openPR
Pfizer Stock Jumps After Reassuring 2025 Guidance - The Wall Street Journal
Medicare Part D Redesign: Pfizer’s Catastrophic Phase Discounts Will Total $1.5bn In 2025 - Citeline News & Insights
Pfizer Confident On Policy Outlook Heading Into Trump Administration - Citeline News & Insights
Pfizer Stock Surges 4% on Reaffirmed Earnings Guidance, Don't Buy Shares Yet - Money Morning
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump: Will 'Knock Out' Pharma Middlemen - Marketscreener.com
Pfizer (NYSE:PFE) Trading Up 4%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Shares Gap UpStill a Buy? - MarketBeat
Trump ‘Middleman’ Remark Sinks CVS, UnitedHealth, Cigna Shares - MSN
Health Insurers Fall as Pfizer CEO Says Trump Wants PBM Reform - Yahoo Finance
Pfizer issues full-year 2025 guidance - Yahoo Finance
Pfizer does not expect major vaccine policy changes under Trump in 2025 - Reuters
Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For? - Yahoo Finance
Pfizer (PFE) technical analysisPfizer (NYSE:PFE) - Benzinga
Pfizer predicts stability, to Wall Street’s relief - BioPharma Dive
Global markets live: Meta Platforms, Pfizer, Broadcom, Nokia, Carlsberg... - Marketscreener.com
Pfizer earnings offer relief to weary investors - Crain's New York Business
Pfizer meets forecasts with 2025 guidance - ShareCast
Pfizer Shares Jump 4% on Positive 2025 Outlook Despite $1B Impact - Yahoo Finance
Pfizer Stock Rises as 2025 Outlook in Line With Expectations - Yahoo Finance
Pfizer’s In-Line Guidance Offers Relief to Weary Investors - Yahoo Finance
2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical - Schaeffers Research
UnitedHealth, CVS Health extend decline as Pfizer CEO cites Trump’s PBM comments - Seeking Alpha
Pfizer issues 2025 outlook in-line with Wall Street, shares rise - Yahoo Finance
Pfizer shares rise despite criticism Starboard, with optimistic 2025 earnings forecast - Marketscreener.com
Pfizer ticks up as expectation-matching guidance relieves investors - Proactive Investors UK
0.84%
1.48%
자본화:
|
볼륨(24시간):